Opendata, web and dolomites

Oximonitor

The first portable monitoring medical device providing accurate prognosis for patients with circulatory failure

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Oximonitor project word cloud

Explore the words cloud of the Oximonitor project. It provides you a very rough idea of what is the project "Oximonitor" about.

microcirculatory    12    learning    400       extracorporeal    sublingually    manner    quantifying    software    treatment    clinical    market    acute    2023    expand    back    odi    data    clinically    individuals    norwegian    millions    17    membrane    surface    oximonitor    predict    generating    viability    cloud    mlab    heart    cells    creates    fingerprint    ip    accurately    costing    platform    machine    decision    life    societal    patients    care    first    2022    computing    patient    incorporates    cumulative    health    proof    likewise    monitoring    function    bedside    cardiac    34    exemplified    39    ecmo    financial    body    cagr    enormous    75    validated    skin    billion    optical    hardware    medical    report    clab    interpretation    roi    dashboard    collecting    sufficient    22    dead    symptom    2017    company    conjunctiva    oxygenation    count    sent    specialists    staff    35    start    neonatal    circulatory    profit    inability    patented    sepsis    recover    survivors    asphyxia    point    monitors    poc    respiratory    site    collects    o2    invasive    worldwide    effectiveness   

Project "Oximonitor" data sheet

The following table provides information about the project.

Coordinator
ODI MEDICAL AS 

Organization address
address: OSLO SCIENCE PARK, GAUSTADALLEEN 21
city: OSLO
postcode: 349
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Norway [NO]
 Project website https://odimedical.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-03-01   to  2019-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ODI MEDICAL AS NO (OSLO) coordinator 50˙000.00

Map

 Project objective

Microcirculatory failure (the inability to deliver sufficient O2 to the cells of the body), is a symptom from several health conditions affecting millions of individuals worldwide (e.g. heart failure, neonatal asphyxia or sepsis). The societal and financial impact of these conditions is enormous, as exemplified by patients in need of cardiac and respiratory support (such as extracorporeal membrane oxygenation life support or ECMO), with only 17% of survivors, while costing up to 1.35 M€ for a 1-year treatment. Specialists cannot predict if these patients are clinically dead or can recover because available medical devices do not allow to monitoring patient´s microcirculatory function. To solve this, at ODI Medical (a Norwegian start-up company) we have developed OXIMONITOR, the first-ever proof-of-concept validated, patented and non-invasive point of care (POC) integrated platform used bedside that accurately monitors microcirculatory function by quantifying O2 delivery and allows to assess the effectiveness of the patient´s treatment of choice, all in a user-friendly manner. OXIMONITOR incorporates: (1) The mLab hardware which creates an “optical fingerprint” of the patient’s circulatory function by collecting data from the surface of the patient’s skin, the conjunctiva or even sublingually. (2) The cLab; a Cloud computing software based on machine learning technology that collects and analyses the data generating the patient´s interpretation report, which is sent back to the clinical site through a user-friendly dashboard for decision-making. The market of cardiac monitoring (our first clinical application) will reach €22 billion by 2022 at a CAGR of 3.9% (2017-2022). With OXIMONITOR we will contribute to the viability of our company, generating a cumulative profit of 34.39 M€ (ROI of 12.75) and growing our staff count 400% by 2023. Likewise, the IP generated by this project will allow us to expand the number of clinical applications using our platform.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OXIMONITOR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OXIMONITOR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Click and Spray (2020)

A SIMPLER, CHEAPER AND EASIER TO RECYCLE AEROSOL CONTAINER

Read More  

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

Primavera (2018)

Primavera: immunobiotics for treating early stage Age-related Macular Degeneration (AMD)

Read More